High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease

Imagem de Miniatura
Arquivos
art_ALVES_High_tumour_burden_delayed_diagnosis_and_history_of_2018.PDF (268.71 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CANCER INTELLIGENCE LTD
Autores
Citação
ECANCERMEDICALSCIENCE, v.12, article ID 879, 9p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Patients with carcinoid syndrome (CS) may present carcinoid heart disease (CHD) but prognostic factors are not entirely understood. Patients and Methods: Retrospective study of patients with metastatic neuroendocrine tumours (NETs) and CS and/or abnormal 24-hour-urinary 5-hydroxiindolacetic acid. CHD was defined as moderate to severe tricuspid or pulmonary regurgitation in the echocardiogram. Results: The frequency of CHD among 42 patients was 38% (95% confidence interval [CI]: 23%-54%). CHD was associated with higher volume of liver metastases (odds ratio [OR] 13.86, 95% CI: 2.57-74.68, p = 0.002). Time from CS symptoms to NET diagnosis was borderline significant (p = 0.08). When CHD was defined as at least mild tricuspide regurgitation, the frequency of CHD was 45% and it was associated with cardiovascular comorbidities (OR: 6.58, 95% CI: 1.09; 39.78, p = 0.040). Conclusion: CHD was frequent among patients with CS, significantly associated with high liver tumour burden, and likely linked to the history of cardiovascular disease and longer time of CS.
Palavras-chave
neuroendocrine tumours, carcinoid syndrome, carcinoid heart, metastases
URI
https://observatorio.fm.usp.br/handle/OPI/29858
Referências
  1. Bergestuen DS, 2010, NEUROENDOCRINOLOGY, V92, P168, DOI 10.1159/000318014
  2. Bhattacharyya S, 2008, AM J CARDIOL, V101, P378, DOI 10.1016/j.amjcard.2007.08.045
  3. Bhattacharyya S, 2013, J HEART VALVE DIS, V22, P400
  4. Bhattacharyya S, 2011, AM J CARDIOL, V107, P1221, DOI 10.1016/j.amjcard.2010.12.025
  5. Bhattacharyya S, 2009, LANCET, V374, P577, DOI 10.1016/S0140-6736(09)60252-X
  6. Davar J, 2017, J AM COLL CARDIOL, V69, P1288, DOI 10.1016/j.jacc.2016.12.030
  7. Gustafsson BI, 2005, CIRCULATION, V111, P1517, DOI 10.1161/01.CIR.0000159356.42064.48
  8. Halperin DM, 2017, LANCET ONCOL, V18, P525, DOI 10.1016/S1470-2045(17)30110-9
  9. HIMELMAN RB, 1989, AM J CARDIOL, V63, P347, DOI 10.1016/0002-9149(89)90344-5
  10. Hutcheson JD, 2011, PHARMACOL THERAPEUT, V132, P146, DOI 10.1016/j.pharmthera.2011.03.008
  11. Kulke MH, 2017, J CLIN ONCOL, V35, P14, DOI 10.1200/JCO.2016.69.2780
  12. Libby P, 2015, CARDIOVASC RES, V107, P307, DOI 10.1093/cvr/cvv188
  13. LUNDIN L, 1988, CIRCULATION, V77, P264, DOI 10.1161/01.CIR.77.2.264
  14. Moller JE, 2003, NEW ENGL J MED, V348, P1005, DOI 10.1056/NEJMoa021451
  15. Mota JM, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.662
  16. Rajamannan NM, 2001, J HEART VALVE DIS, V10, P827
  17. Riechelmann RP, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.716
  18. ROBIOLIO PA, 1995, CIRCULATION, V92, P790, DOI 10.1161/01.CIR.92.4.790
  19. Schmidinger M, 2008, J CLIN ONCOL, V26, P5204, DOI 10.1200/JCO.2007.15.6331
  20. Soultati A, 2012, CANCER TREAT REV, V38, P473, DOI 10.1016/j.ctrv.2011.09.002
  21. Zacks J, 2016, 13 ANN ENETS C BARC

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/08
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03